Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 4/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | HAT1 | O14929 | 2/20 | 0.36 |
| ▸ | EP300 | Q09472 | 2/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25742029 | 0.90 | HTR3A (0.44) | CNR1CNR2HTR3AICMT | |
| SCHEMBL26261191 | 0.85 | HAT1 (0.43) | CNR1CNR2NR4A2HAT1EP300 | |
| SCHEMBL25742001 | 0.85 | IDO1 (0.47) | CNR1CNR2MEN1KMT2AHTR3A | |
| SCHEMBL25742012 | 0.83 | CNR1 (0.42) | CNR1CNR2MEN1KMT2ANR4A2 | |
| SCHEMBL25742015 | 0.82 | CNR1 (0.41) | CNR1CNR2MEN1KMT2ANR4A2 | |
| SCHEMBL25742052 | 0.80 | CNR1 (0.43) | CNR1CNR2MEN1KMT2ANR4A2 | |
| SCHEMBL12486009 | 0.80 | CNR1 (0.48) | CNR1CNR2MEN1KMT2ANR4A2 | |
| SCHEMBL25742077 | 0.79 | CNR1 (0.43) | CNR1CNR2MEN1KMT2ANR4A2 | |
| SCHEMBL25742058 | 0.79 | CNR1 (0.43) | CNR1CNR2MEN1KMT2ANR4A2 | |
| SCHEMBL26261215 | 0.78 | HAT1 (0.45) | CNR1CNR2MEN1KMT2ANR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | HTR6, TPH2, TPH1 | CNR1 118/4885CNR2 47/4885MEN1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.